Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 02, 2013, 16:00 ET
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update - In January 2013, the Company initiated the...
More news about: OncoGenex Pharmaceuticals, Inc. , Teva Pharmaceutical Industries Ltd.
-
Apr 11, 2013, 08:00 ET
OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previously untreated advanced non-squamous non-small...
More news about: OncoGenex Pharmaceuticals, Inc. , Teva Pharmaceutical Industries Ltd.
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |